Danish drugmaker Novo Nordisk (NVO) said its new survey in the U.S. shows that its weight loss drug, Wegovy, helps to douse “food noise” among 46% of users who took the injection treatment. Food noise is an unwanted and intrusive constant thought about food that can impede a weight loss effort.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novo Nordisk’s update, which follows an earlier one disclosing that a triple dose of the prescription drug helped patients achieve a 19% weight loss, sent American rival Eli Lilly’s (LLY) shares down by almost 1% at the closing bell on Monday.
Wevogy Boosts Mental Health, Novo Nordisk Says
Furthermore, Novo Nordisk reported that taking Wegovy enabled users in the survey to achieve a significant improvement in their mental well-being and lifestyle. However, the Danish pharmaceutical company did not disclose the number of users who participated in the survey.
Novo Nordisk presented the findings of the survey at the European Association for the Study of Diabetes 2025 in Vienna, Austria. The survey also reported that the number of users who said food noise impacted their lives dropped from 60% to 20% after they started undergoing a Wegovy treatment plan.
In addition, the survey outlined that about 67% of users recorded an improved mental health boost after they started taking the weight-loss drug. This follows an even greater majority (76%) who reported adopting healthier lifestyles and habits.
Big Pharma Companies Compete in the Weight-Loss Market
Novo Nordisk’s latest revelation builds on the competition between pharmaceuticals, including key rivals Eli Lilly and Novo Nordisk, that are vying for bigger control of the growing weight-loss drug market. While Novo Nordisk promotes Wegovy and the diabetes drug Ozempic, Eli Lilly is the brain behind Zepbound for weight loss and Mounjaro for diabetes.
Meanwhile, the new update also follows the recent release of data that suggested that Novo Nordisk’s Wegovy performed better in protecting the heart, compared to Eli Lilly’s weight-loss drug. However, Novo Nordisk appears to be losing ground in the U.S. to its rival.
Over the past year, the Danish company’s shares listed in the U.S. have plunged nearly 60%, in contrast to Eli Lilly’s 19% drop. Novo Nordisk also recently announced a major restructuring, slashing 11% of its global workforce.
Is Novo Nordisk a Buy, Sell, or Hold?
On TipRanks, Novo Nordisk’s shares have a Moderate Buy consensus recommendation based on four Buys and four Holds assigned by eight Wall Street analysts over the past three months. The average NVO price target is $67.71, which suggests a 22% growth potential from its current level.
